Steris Plc's ROA from the fourth quarter of 2026 to the fourth quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Steris Plc's ROA in the fourth quarter of 2026?
Steris Plc achieved a return on average assets (ROA) of 7.62 % in its fourth quarter of 2026, this is above STE's average return on assets of 5.14%.
Steris Plc assets over the 12 months ending in its fourth quarter of 2026 are valued at $10,306 million

ROA has improved compared to 7.02% in the third quarter of 2026, due to net income growth.

However, within the Healthcare sector 122 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Mar 31 2026 quarter, so far to 830, from total ROA ranking in the third quarter of 2026 at 1049.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Mar 31 2026) IV. Quarter	(Dec 31 2025) III. Quarter	(Sep 30 2025) II. Quarter	(Jun 30 2025) I. Quarter	(Mar 31 2025) IV. Quarter
Y / Y Total Assets Change	7.45 %	-8.25 %	1.64 %	3 %	-8.25 %
Y / Y Net Income Change	50.81 %	12.13 %	27.34 %	22.3 %	-
Net Income (TTM) in million	785	711	690	649	616
Return On Assets (TTM)	7.62 %	7.02 %	6.67 %	6.29 %	6.02 %
STE's Total Ranking	# 830	# 1049	# 937	# 991	# 1040
Total Assets (TTM) in million	10,737	9,992	10,251	10,244	9,992
Seq. Total Assets Change	7.45 %	-2.52 %	0.07 %	2.52 %	-8.25 %
Seq. Net Income Change	13.38 %	0.94 %	8.15 %	21.86 %	-15.7 %

STE's 5 Years Annual ROA >> Back to STE Management Effectiveness >> Compare STE ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 36
Sector	# 123
Overall	# 825

Return On Assets Statistics
High	Average	Low
9.75 %	5.14 %	-0.99 %
(Mar 31 2013)		(Sep 30 2022)

Financial Statements
Steris Plc's Assets	$ 10,737 million	STE's Balance sheet
Steris Plc's Income	$ 220 million	Quarterly STE's Income Statement
STE's Income by Division		See STE's Income by Division

Annual Return On Assets	(Mar 31 2026) FY 2026	(Mar 31 2025) FY 2025	(Mar 31 2024) FY 2024	(Mar 31 2023) FY 2023	(Mar 31 2018) FY 2018
Y / Y Total Assets Change	7.45 %	-8.25 %	2.44 %	104.45 %	5.6 %
Total Assets in million	10,737	9,992	10,891	10,632	5,200
Y / Y Net Income Change	27.44 %	62.09 %	259.2 %	-63.72 %	163.6 %
Net Income in million	785	616	380	106	292
Annual Return On Assets	7.31 %	6.17 %	3.49 %	1 %	5.61 %

STE's 5 Years Annual ROA >> Back to STE Management Effectiveness >> Compare STE ROA to its Competitors

Comment on STE's ROA in the fiscal year ending 2026

In the fiscal year 2026 ROA improved to 7.31 % compared to prior year, due to annual net income growth of 27.44 % to $785.10 million, while value of Steris Plc's overall assets grew just by 7.45 % to $10,737.20 million, compared to $10,737.20 a year before.

More Return On Assets Ratios
STE's' Return on Assets at Yahoo Finance
Medical Equipment & Supplies Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
STE's Roa Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for STE's Competitors
Subscribers only: Roa for Steris Plc's Suppliers
Subscribers only: Return On Assets for STE's Customers

You may also want to know
STE's Roi	STE's Inventory Turnover Ratio	STE's Growth Rates	STE's Dividend Comparisons
	STE's Profitability Ratios	STE's Asset Turnover Ratio	STE's Dividend Growth
STE's Roe	STE's Valuation Ratios	STE's Financial Strength Ratios	STE's Dividend Payout Ratio

Companies with similar Return On Assets at Mar 31 2026, within Healthcare Sector	ROA
Catalyst Pharmaceuticals Inc	20.71 %
Engene Therapeutics Inc	20.52 %
Vaxart Inc	20.07 %
Indivior Pharmaceuticals Inc	19.14 %
Pro dex Inc	18.35 %
Electromed Inc	18.31 %
Soleno Therapeutics Inc	18.25 %
Resmed Inc	18.18 %
Protalix Biotherapeutics inc	17.75 %
Krystal Biotech Inc	17.62 %
Zoetis Inc	17.60 %
United Therapeutics Corporation	17.25 %
Vertex Pharmaceuticals Inc	17.18 %
Chemed Corporation	16.20 %
Gilead Sciences Inc	16.06 %
Transmedics Group Inc	15.85 %
Inspire Medical Systems inc	15.30 %
Neurocrine Biosciences Inc	15.12 %
Strata Critical Medical Inc	15.09 %
Intuitive Surgical Inc	14.98 %
Halozyme Therapeutics Inc	14.73 %
Profound Medical Corp	13.91 %
Aveanna Healthcare Holdings Inc	13.73 %
Standard Biotools Inc	13.58 %
Illumina Inc	13.40 %
Dexcom Inc	13.39 %
West Pharmaceutical Services Inc	13.21 %
Apellis Pharmaceuticals Inc	13.20 %
Prestige Consumer Healthcare Inc	13.01 %
Hca Healthcare Inc	12.94 %

Date modified: 2026-08-14T21:16:43+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.